House Democrats contend the $15 per hour minimum wage bill will lift workers who have not seen the benefits of a strong economy.Politicsread more
Analysts think Microsoft's Azure cloud growth slowed in the fiscal fourth quarter. But Windows revenue could benefit from better-than-expected PC sales.Technologyread more
Trump said the USS Boxer fired on and destroyed Iran's drone in the Strait of Hormuz on Thursday in a "defensive action."Politicsread more
Stocks erased earlier losses, but the rise was kept in check as Wall Street digested a mixed batch of corporate earnings results.US Marketsread more
The Philadelphia Fed saw its primary gauge measuring the sector jump from 0.3 in June to 21.8, far better than Wall Street estimates of 5 and the highest in a year.Economyread more
"It's better to take preventative measures than to wait for disaster to unfold," Williams told the annual meeting of the Central Bank Research Association.The Fedread more
The fact that interest rates are relatively low makes the idea of a so-called insurance rate cut later this month an attractive option for the Fed.Market Insiderread more
Video of the event does not show the president disagreeing with his supporters. Instead, it shows that Trump paused as the chant began, allowing his supporters to continue...Politicsread more
President Trump said he's looking at the JEDI Contract that will be awarded to Microsoft or Amazon.Technologyread more
Wealthy clients liquidate some investments every year to cover their tax bill, so presumably this was higher than what Morgan Stanley has seen previously.Financeread more
Hacker Square at Facebook's headquarters pays homage to the company's early motto of moving fast and breaking things.Technologyread more
Shares of Valeant Pharmaceuticals rose more than 6 percent Monday after a Mizuho Securities analyst who had been bearish on the stock upgraded it.
"Because there is now a lower likelihood of a stock collapse from another guidance miss," Mizuho's Irina Koffler said in a research note, "we think our short thesis has been debunked and are upgrading VRX to neutral with a $25 [price target] based entirely on an optimistic [sum-of-the-parts] analysis."
Koffler previously rated the stock "underperform" and had a prior price target of $11 per share.
Last week, sources told Reuters that Valeant offered to pay lenders a higher interest rate in order to amend its debt agreements. This move loosened its interest coverage ratio requirement and now provides Valeant more breathing room.
As a result of the new terms, the analyst isn't as worried about what would happen if the company were to miss its future earnings targets.
Koffler said she continues to see Valeant's full-year earnings forecast as "unrealistic," given the expected 2.2 percent sequential decline in the revenue of its top 30 products and the pressure it is under to cut costs in its daily operations.
Valeant has about $30.77 billion in debt. The company had to appease creditors earlier this year after it missed deadlines for filing financial reports, triggering default notices.
Management said it plans to divest noncore assets, but Koffler also suspects the company's projected value for these assets is "highly aspirational." And she said she expects some of the assets will not attract buyers.
Valeant on Tuesday posted second-quarter earnings of $1.40 a share on $2.42 billion in revenue. Analysts had expected earnings of $1.48 a share on $2.46 billion in revenue, according to Thomson Reuters.
The drugmaker said it maintains its full-year 2016 adjusted earnings of $6.60 to $7 a share on revenue of $9.9 billion to $10.1 billion. Analysts estimate the company will earn $6.53 a share, according to Thomson Reuters.
Valeant declined to comment. The company's stock has fallen more than 73 percent this year.
VRX 2016 Chart